Shares of Zafgen (ZFGN) have risen by 115% since I originally suggested readers take a position in this turnaround idea which was essentially valued at its cash position while targeting large market opportunities with its second generation MetAP2 inhibitor ZGN-1061.
After the second quarter update, I decided it was time to reevaluate looking ahead to the second half of the year.
Chart
Figure 1: ZFGN daily advanced chart (Source: Finviz)
Figure 2: ZFGN 15-minute chart (Source: Finviz)
When looking at charts, clarity often comes from taking a look at distinct time frames in